Unknown

Dataset Information

0

Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy.


ABSTRACT: The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic efficiencies of small-molecule drugs. In this work, two novel oxidative/reductive (Ox/Re) -sensitive and one non-sensitive Paclitaxel (PTX) prodrugs were synthesized with a maleimide group, which rapidly conjugates with albumin in vivo. Albumin serves as a good vehicle to deliver more prodrug to tumors due to the enhanced permeation and retention (EPR) effect. PTX was then released from the prodrugs in glutathione(GSH)/ reactive oxygen species(ROS)-rich tumor microenvironments. This bioresponsive prodrug strategy demonstrates potent chemotherapeutic efficiency in vivo and may be utilized in clinical cancer therapy.

SUBMITTER: Yang J 

PROVIDER: S-EPMC6058529 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8399365 | biostudies-literature
| S-EPMC7090179 | biostudies-literature
| S-EPMC5327637 | biostudies-literature
| S-EPMC5501509 | biostudies-literature
| S-EPMC7388541 | biostudies-literature
| S-EPMC5495651 | biostudies-literature
| S-EPMC5433896 | biostudies-literature
| S-EPMC5858514 | biostudies-other
| S-EPMC7594083 | biostudies-literature
| S-EPMC5583572 | biostudies-literature